Alkahest Initiates a Phase 2 Clinical Trial of AKST4290 in Parkinson’s Disease with Funding from The Michael J. Fox Foundation

Alkahest Initiates a Phase 2 Clinical Trial of AKST4290 in Parkinson’s Disease with Funding from The Michael J. Fox Foundation
SAN CARLOS, Calif., Feb. 04, 2020 (GLOBE NEWSWIRE) -- Alkahest, Inc., a clinical stage biotechnology company focused on developing transformative therapies to treat age-related diseases, today ... read more
Source: Bing NewsPublished on 2020-02-03